Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, Asahina M, Fukushi K, Kuwabara S, Hattori T, Suhara T, Irie T
Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 260-8555, Japan.
Neurology. 2009 Jul 28;73(4):273-8. doi: 10.1212/WNL.0b013e3181ab2b58. Epub 2009 May 27.
To characterize brain cholinergic deficits in Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB).
Participants included 18 patients with PD, 21 patients with PDD/DLB, and 26 healthy controls. The PD group consisted of nine patients with early PD, each with a disease duration of less than 3 years, five of whom were de novo PD patients, and nine patients with advanced PD, each with a disease duration greater than or equal to 3 years. The PDD/DLB group consisted of 10 patients with PDD and 11 patients with DLB. All subjects underwent PET scans with N-[11C]-methyl-4-piperidyl acetate to measure brain acetylcholinesterase (AChE) activity. Brain AChE activity levels were estimated voxel-by-voxel in a three-compartment analysis using the arterial input function, and compared among our subject groups through both voxel-based analysis using the statistical parametric mapping software SPM5 and volume-of-interest analysis.
Among patients with PD, AChE activity was significantly decreased in the cerebral cortex and especially in the medial occipital cortex (% reduction compared with the normal mean = -12%) (false discovery rate-corrected p value <0.01). Patients with PDD/DLB, however, had even lower AChE activity in the cerebral cortex (% reduction = -27%) (p < 0.01). There was no significant difference between early PD and advanced PD groups or between DLB and PDD groups in the amount by which regional AChE activity in the brain was reduced.
Brain cholinergic dysfunction occurs in the cerebral cortex, especially in the medial occipital cortex. It begins in early Parkinson disease, and is more widespread and profound in both Parkinson disease with dementia and dementia with Lewy bodies.
描述帕金森病(PD)、帕金森病痴呆(PDD)和路易体痴呆(DLB)患者脑胆碱能缺陷情况。
参与者包括18例PD患者、21例PDD/DLB患者和26名健康对照者。PD组由9例早期PD患者组成,每位患者病程均小于3年,其中5例为初发PD患者,以及9例晚期PD患者,每位患者病程均大于或等于3年。PDD/DLB组由10例PDD患者和11例DLB患者组成。所有受试者均接受用N-[11C]-甲基-4-哌啶乙酸进行的PET扫描,以测量脑乙酰胆碱酯酶(AChE)活性。在三室分析中使用动脉输入函数逐体素估计脑AChE活性水平,并通过使用统计参数映射软件SPM5的基于体素的分析和感兴趣区分析在我们的受试者组之间进行比较。
在PD患者中,大脑皮质尤其是枕内侧皮质的AChE活性显著降低(与正常均值相比降低百分比=-12%)(错误发现率校正p值<0.01)。然而,PDD/DLB患者大脑皮质的AChE活性更低(降低百分比=-27%)(p<0.01)。早期PD组和晚期PD组之间或DLB组和PDD组之间在脑局部AChE活性降低量方面无显著差异。
脑胆碱能功能障碍发生在大脑皮质,尤其是枕内侧皮质。它始于早期帕金森病,在帕金森病痴呆和路易体痴呆中更广泛且更严重。